{"prompt": "['Short Title: ACADEMIC: ADT + Docetaxel vs ADT + Abiraterone', 'Version Date: 13MAR2019', 'Yonsa', 'Hypertension, Hypokalemia and Fluid Retention Due to Mineralocorticoid Excess:', 'Yonsa may cause hypertension, hypokalemia, and fluid retention as a consequence of increased', 'mineralocorticoid levels resulting from CYP17 inhibition. Monitor patients for hypertension,', 'hypokalemia, and fluid retention at least once a month. Control hypertension and correct', 'hypokalemia before and during treatment with Yonsa.', 'In the two randomized clinical trials, grade 3 to 4 hypertension occurred in 2% of patients,', 'grade 3 to 4 hypokalemia in 4% of patients, and grade 3 to 4 edema in 1% of patients treated', 'with abiraterone acetate.', 'Co-administration of a corticosteroid suppresses adrenocorticotropic hormone (ACTH) drive,', 'resulting in a reduction in the incidence and severity of these adverse reactions. Closely', 'monitor patients whose underlying medical conditions might be compromised by increases in', 'blood pressure, hypokalemia or fluid retention, such as those with heart failure, recent', 'myocardial infarction, cardiovascular disease, or ventricular arrhythmia. The safety of Yonsa', 'in patients with left ventricular ejection fraction < 50% or New York Heart Association', '(NYHA) Class III or IV heart failure (in Study 1) or NYHA Class II to IV heart failure (in', 'Study 2) was not established because these patients were excluded from these randomized', 'clinical trials.', 'Adrenocortical Insufficiency:', 'Adrenal insufficiency occurred in the two randomized clinical studies in 0.5% of patients', 'taking abiraterone acetate and in 0.2% of patients taking placebo. Adrenocortical insufficiency', 'was reported in patients receiving abiraterone acetate in combination with corticosteroid,', 'following interruption of daily steroids and/or with concurrent infection or stress.', 'Monitor patients for symptoms and signs of adrenocortical insufficiency, particularly if', 'patients are withdrawn from corticosteroids, have corticosteroid dose reductions, or experience', 'unusual stress. Symptoms and signs of adrenocortical insufficiency may be masked by adverse', 'reactions associated with mineralocorticoid excess seen in patients treated with Yonsa. If', 'clinically indicated, perform appropriate tests to confirm the diagnosis of adrenocortical', 'insufficiency. Increased dosage of corticosteroids may be indicated before, during and after', 'stressful situations.', 'Hepatotoxicity:', 'In postmarketing experience, there have been abiraterone acetate-associated severe hepatic', 'toxicity, including fulminant hepatitis, acute liver failure and deaths.', 'In the two randomized clinical trials, grade 3 or 4 ALT or AST increases (at least 5X ULN)', 'were reported in 4% of patients who received abiraterone acetate, typically during the first 3', 'months after starting treatment. Patients whose baseline ALT or AST were elevated were more', 'likely to experience liver test elevation than those beginning with normal values. Treatment', 'discontinuation due to liver enzyme increases occurred in 1% of patients taking abiraterone', 'acetate. No deaths clearly related to abiraterone acetate were reported due to hepatotoxicity', 'events.', 'Measure serum transaminases (ALT and AST) and bilirubin levels prior to starting treatment', 'with Yonsa, every two weeks for the first three months of treatment and monthly thereafter. In', 'Page 18 of 52']['Short Title: ACADEMIC: ADT + Docetaxel vs ADT + Abiraterone', 'Version Date: 13MAR2019', 'patients with baseline moderate hepatic impairment receiving a reduced Yonsa dose of 125', 'mg, measure ALT, AST, and bilirubin prior to the start of treatment, every week for the first', 'month, every two weeks for the following two months of treatment and monthly thereafter.', 'Promptly measure serum total bilirubin, AST, and ALT if clinical symptoms or signs', \"suggestive of hepatotoxicity develop. Elevations of AST, ALT, or bilirubin from the patient's\", 'baseline should prompt more frequent monitoring. If at any time AST or ALT rise above five', 'times the ULN, or the bilirubin rises above three times the ULN, interrupt Yonsa treatment and', 'closely monitor liver function.', 'Re-treatment with Yonsa at a reduced dose level may take place only after return of liver', \"function tests to the patient's baseline or to AST and ALT less than or equal to 2.5X ULN and\", 'total bilirubin less than or equal to 1.5X ULN. Permanently discontinue treatment with', 'abiraterone acetate for patients who develop a concurrent elevation of ALT greater than 3 X', 'ULN and total bilirubin greater than 2 X ULN in the absence of biliary obstruction or other', 'causes responsible for the concurrent elevation. The safety of YONSA re-treatment of patients', 'who develop AST or ALT greater than or equal to 20X ULN and/or bilirubin greater than or', 'equal to 10X ULN is unknown.', '4', 'STUDY DESIGN', '4.1', 'Description', 'This is an open label, randomized prospective clinical trial. All patients will be treated with', 'ongoing standard of care ADT (surgical or medical castration, documented testosterone < 50', 'ng/dL while on study) plus either docetaxel intravenously (75mg/m2) once every 3 weeks for', '6 cycles or abiraterone orally until disease progression. Treatment will occur per standard of', 'care at the discretion of the treating physician. Radiographic disease assessment will be', 'performed per clinical indication. Study visits time points will be based on day 1 of treatment', 'and follow a consistent schedule, regardless of treatment delays. Patients will be followed until', 'disease progression or for 18 months, whichever occurs first.', '4.2', 'Number of Patients', 'A total of 89 subjects will be enrolled.', '4.3', 'Number of Study Centers', 'This will be a multi-institution trial conducted at the Huntsman Cancer Institute, at the', 'University of Utah. Up to an additional 7 other centers may be opened.', '4.4', 'Study Duration', 'This trial is expected complete enrollment within 24 months. Treatment is expected to continue', 'for an additional 18 months. The study will be completed after approximately 42 months.', 'Page 19 of 52']\n\n###\n\n", "completion": "END"}